Bergenbio ASA Valuation
| BGBIO Stock | NOK 12.70 2.72 27.25% |
At this time, the firm appears to be overvalued. Bergenbio ASA shows a prevailing Real Value of 9.19 per share. The current price of the firm is 12.7. Our model approximates the value of Bergenbio ASA from analyzing the firm fundamentals such as Operating Margin of (383.14) %, shares outstanding of 88.66 M, and Return On Equity of -0.96 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Bergenbio ASA's price fluctuation is relatively risky at this time. Calculation of the real value of Bergenbio ASA is based on 3 months time horizon. Increasing Bergenbio ASA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bergenbio ASA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bergenbio Stock. However, Bergenbio ASA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.7 | Real 9.19 | Hype 12.7 |
The intrinsic value of Bergenbio ASA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bergenbio ASA's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bergenbio ASA helps investors to forecast how Bergenbio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bergenbio ASA more accurately as focusing exclusively on Bergenbio ASA's fundamentals will not take into account other important factors: Bergenbio ASA Total Value Analysis
Bergenbio ASA is currently estimated to have takeover price of 421.26 M with market capitalization of 609.1 M, debt of 942 K, and cash on hands of 436.65 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Bergenbio ASA fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
421.26 M | 609.1 M | 942 K | 436.65 M |
Bergenbio ASA Investor Information
About 35.0% of the company shares are held by company insiders. The book value of Bergenbio ASA was currently reported as 1.86. The company recorded a loss per share of 3.5. Bergenbio ASA had not issued any dividends in recent years. The entity had 100:1 split on the 25th of May 2024. Based on the key measurements obtained from Bergenbio ASA's financial statements, Bergenbio ASA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Bergenbio ASA Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bergenbio ASA has an asset utilization ratio of 0.17 percent. This suggests that the Company is making 0.001719 for each dollar of assets. An increasing asset utilization means that Bergenbio ASA is more efficient with each dollar of assets it utilizes for everyday operations.Bergenbio ASA Ownership Allocation
Bergenbio ASA holds a total of 88.66 Million outstanding shares. Bergenbio ASA retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Bergenbio ASA Profitability Analysis
The company reported the revenue of 774 K. Net Loss for the year was (309.36 M) with profit before overhead, payroll, taxes, and interest of 774 K.About Bergenbio ASA Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Bergenbio ASA. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Bergenbio ASA based exclusively on its fundamental and basic technical indicators. By analyzing Bergenbio ASA's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Bergenbio ASA's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bergenbio ASA. We calculate exposure to Bergenbio ASA's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bergenbio ASA's related companies.BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. The company was founded in 2007 and is headquartered in Bergen, Norway. BerGenBio ASA is traded on Oslo Stock Exchange in Norway.
8 Steps to conduct Bergenbio ASA's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Bergenbio ASA's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Bergenbio ASA's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Bergenbio ASA's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Bergenbio ASA's revenue streams: Identify Bergenbio ASA's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Bergenbio ASA's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Bergenbio ASA's growth potential: Evaluate Bergenbio ASA's management, business model, and growth potential.
- Determine Bergenbio ASA's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Bergenbio ASA's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Other Information on Investing in Bergenbio Stock
Bergenbio ASA financial ratios help investors to determine whether Bergenbio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bergenbio with respect to the benefits of owning Bergenbio ASA security.